KokkinidisDGJawaidOCantuD, et al. Two-year outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of heavily calcified femoropopliteal lesions. J Endovasc Ther. 2020;27:492–501.
2.
DotterCTJudkinsMP.Transluminal treatment of arteriosclerotic obstruction. description of a new technic and a preliminary report of its application. Circulation. 1964;30:654–670.
3.
KasapisCHenkePKChetcutiSJ, et al. Routine stent implantation vs. percutaneous transluminal angioplasty in femoropopliteal artery disease: a meta-analysis of randomized controlled trials. Eur Heart J. 2009;30:44–55.
4.
ZhouYZhangZLinS, et al. Comparative effectiveness of endovascular treatment modalities for de novo femoropopliteal lesions: a network meta-analysis of randomized controlled trials. J Endovasc Ther. 2020;27:42–59.
5.
IidaOUrasawaKKomuraY, et al. Self-expanding nitinol stent vs percutaneous transluminal angioplasty in the treatment of femoropopliteal lesions: 3-year data from the SM-01 trial. J Endovasc Ther. 2019;26:158–167.
6.
ClarkTWGroffskyJLSoulenMC.Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol. 2001;12:923–933.
7.
KrankenbergHSchlüterMSteinkampHJ, et al. Nitinol stent implantation versus percutaneous transluminal angioplasty in superficial femoral artery lesions up to 10 cm in length: the femoral artery stenting trial (FAST). Circulation. 2007;116:285–292.
8.
SchillingerMSabetiSLoeweC, et al. Balloon angioplasty versus implantation of nitinol stents in the superficial femoral artery. N Engl J Med. 2006;354:1879–1888.
9.
LairdJRKatzenBTScheinertD; RESILIENT Investigators. Nitinol stent implantation vs. balloon angioplasty for lesions in the superficial femoral and proximal popliteal arteries of patients with claudication: three-year follow-up from the RESILIENT randomized trial. J Endovasc Ther. 2012;19:1–9.
10.
DudaSHBosiersMLammerJ, et al. Drug-eluting and bare nitinol stents for the treatment of atherosclerotic lesions in the superficial femoral artery: long-term results from the SIROCCO trial. J Endovasc Ther. 2006;13:701–710.
11.
DakeMDAnselGMJaffMR, et al; Zilver PTX Investigators. Durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery: 5-year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483.
12.
TepeGSchnorrBAlbrechtT, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8(1pt A):102–108.
13.
RosenfieldKJaffMRWhiteCJ, et al; LEVANT 2 Investigators. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145–153.
14.
LairdJRSchneiderPATepeG, et al; IN.PACT SFA Trial Investigators. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329–2338.
15.
FoleyTRCotterRPKokkinidisDG, et al. Mid-term outcomes of orbital atherectomy combined with drug-coated balloon angioplasty for treatment of femoropopliteal disease. Catheter Cardiovasc Interv. 2017;89:1078–1085.
16.
ShammasNWShammasGAJones-MillerS, et al. Long-term outcomes with JetStream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE). Cardiovasc Revasc Med. 2018;19(7pt A):771–777.
17.
ZellerTLanghoffRRocha-SinghKJ, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017;10:e004848. doi:10.1161/CIRCINTERVENTIONS.116.004848
18.
BanerjeeSJeon-SlaughterHArmstrongEJ, et al. Clinical outcomes and cost comparisons of stent and non-stent interventions in infrainguinal peripheral artery disease: insights from the Excellence in Peripheral Artery Disease (XLPAD) Registry. J Invasive Cardiol. 2019;31:1–9.
19.
PietzschJBGeislerBPGarnerAM, et al. Economic analysis of endovascular interventions for femoropopliteal arterial disease: a systematic review and budget impact model for the United States and Germany. Catheter Cardiovasc Interv. 2014;84:546–554.
20.
FakhryFFokkenroodHJSpronkS, et al. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev. 2018;3:CD010512. doi:10.1002/14651858.CD010512.pub2
21.
van den HoutenMMLHagemanDGommansLNM, et al. The effect of supervised exercise, home based exercise and endovascular revascularisation on physical activity in patients with intermittent claudication: a network meta-analysis. Eur J Vasc Endovasc Surg. 2019;58:383–392.
22.
NorgrenLHiattWRDormandyJA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45(suppl S):S5–S67.
